Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 17 | 2025 | 534 | 3.320 |
Why?
|
| Tumor Suppressor Protein p53 | 10 | 2021 | 714 | 1.060 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 5 | 2017 | 78 | 1.030 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 764 | 0.810 |
Why?
|
| Fatty Acids | 1 | 2022 | 350 | 0.630 |
Why?
|
| N-Myc Proto-Oncogene Protein | 6 | 2022 | 56 | 0.600 |
Why?
|
| Chromatin Assembly Factor-1 | 2 | 2021 | 9 | 0.600 |
Why?
|
| Cell Line, Tumor | 12 | 2025 | 3436 | 0.460 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 412 | 0.450 |
Why?
|
| Imidazoles | 4 | 2015 | 210 | 0.430 |
Why?
|
| Piperazines | 3 | 2013 | 243 | 0.390 |
Why?
|
| Apoptosis | 5 | 2021 | 1795 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 1918 | 0.330 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2021 | 926 | 0.310 |
Why?
|
| Tumor Lysis Syndrome | 2 | 2005 | 9 | 0.240 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 1738 | 0.240 |
Why?
|
| Enzyme Inhibitors | 2 | 2021 | 563 | 0.240 |
Why?
|
| Gangliosides | 1 | 2025 | 66 | 0.230 |
Why?
|
| Oncolytic Virotherapy | 1 | 2025 | 89 | 0.220 |
Why?
|
| Bacteriophages | 1 | 2025 | 86 | 0.210 |
Why?
|
| Animals | 16 | 2025 | 33094 | 0.210 |
Why?
|
| G1 Phase | 1 | 2024 | 65 | 0.210 |
Why?
|
| Mice | 14 | 2021 | 17528 | 0.200 |
Why?
|
| Cell Differentiation | 3 | 2021 | 1848 | 0.190 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2021 | 17 | 0.180 |
Why?
|
| Cyclopentanes | 1 | 2021 | 20 | 0.180 |
Why?
|
| Aurora Kinase A | 1 | 2021 | 34 | 0.170 |
Why?
|
| MicroRNAs | 4 | 2018 | 864 | 0.170 |
Why?
|
| HCT116 Cells | 2 | 2013 | 54 | 0.170 |
Why?
|
| Gene Amplification | 1 | 2021 | 226 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 601 | 0.160 |
Why?
|
| Transcription Factors | 2 | 2024 | 2337 | 0.160 |
Why?
|
| Oncogene Proteins | 2 | 2011 | 132 | 0.160 |
Why?
|
| Circulating MicroRNA | 1 | 2018 | 10 | 0.150 |
Why?
|
| Carcinogenesis | 1 | 2021 | 336 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2021 | 390 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 678 | 0.140 |
Why?
|
| para-Aminobenzoates | 1 | 2017 | 4 | 0.140 |
Why?
|
| Pyrrolidines | 1 | 2017 | 42 | 0.130 |
Why?
|
| Humans | 23 | 2025 | 125613 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 565 | 0.130 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 166 | 0.130 |
Why?
|
| Serum | 1 | 2016 | 43 | 0.130 |
Why?
|
| RNA, Transfer | 1 | 2016 | 68 | 0.130 |
Why?
|
| Proteins | 1 | 2021 | 1017 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2015 | 15 | 0.120 |
Why?
|
| Sirolimus | 1 | 2017 | 224 | 0.120 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2015 | 23 | 0.120 |
Why?
|
| Gene Silencing | 2 | 2013 | 224 | 0.120 |
Why?
|
| Urate Oxidase | 2 | 2005 | 16 | 0.110 |
Why?
|
| Quinolines | 1 | 2015 | 111 | 0.110 |
Why?
|
| Cell Proliferation | 2 | 2021 | 2383 | 0.110 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 1207 | 0.110 |
Why?
|
| Neoplasms | 3 | 2024 | 2814 | 0.100 |
Why?
|
| Mice, Nude | 4 | 2021 | 701 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 1007 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1560 | 0.100 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2013 | 10 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2013 | 408 | 0.100 |
Why?
|
| Neurons | 1 | 2021 | 1908 | 0.090 |
Why?
|
| Zebrafish | 2 | 2025 | 398 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 198 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2024 | 581 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1299 | 0.080 |
Why?
|
| Histones | 1 | 2013 | 503 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 236 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 1774 | 0.080 |
Why?
|
| Transplantation, Heterologous | 3 | 2018 | 246 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 223 | 0.070 |
Why?
|
| Cell Survival | 2 | 2021 | 824 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 426 | 0.070 |
Why?
|
| Disease Progression | 1 | 2013 | 2102 | 0.070 |
Why?
|
| Prognosis | 2 | 2013 | 4668 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1219 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 541 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 1217 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2006 | 231 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 4419 | 0.060 |
Why?
|
| Photosensitizing Agents | 1 | 2025 | 37 | 0.060 |
Why?
|
| Photochemotherapy | 1 | 2025 | 41 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2015 | 4446 | 0.060 |
Why?
|
| Inhibins | 2 | 2002 | 85 | 0.060 |
Why?
|
| Hyperuricemia | 1 | 2005 | 38 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2013 | 4878 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2021 | 1208 | 0.050 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2024 | 144 | 0.050 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2024 | 112 | 0.050 |
Why?
|
| Gonads | 1 | 2003 | 32 | 0.050 |
Why?
|
| Gonadal Disorders | 1 | 2002 | 1 | 0.050 |
Why?
|
| Puberty | 1 | 2003 | 103 | 0.050 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2002 | 58 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2024 | 265 | 0.050 |
Why?
|
| NEDD8 Protein | 1 | 2021 | 11 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 1289 | 0.040 |
Why?
|
| ARNTL Transcription Factors | 1 | 2021 | 44 | 0.040 |
Why?
|
| Lipogenesis | 1 | 2021 | 62 | 0.040 |
Why?
|
| Benzamides | 1 | 2021 | 117 | 0.040 |
Why?
|
| Female | 9 | 2021 | 67790 | 0.040 |
Why?
|
| Human Growth Hormone | 1 | 2001 | 76 | 0.040 |
Why?
|
| Chromatin | 1 | 2024 | 488 | 0.040 |
Why?
|
| Body Height | 1 | 2001 | 190 | 0.040 |
Why?
|
| Male | 9 | 2021 | 61966 | 0.040 |
Why?
|
| Growth Disorders | 1 | 2001 | 184 | 0.040 |
Why?
|
| Gene Expression | 2 | 2016 | 1486 | 0.040 |
Why?
|
| Gene Editing | 1 | 2021 | 195 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 1427 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2005 | 601 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1599 | 0.030 |
Why?
|
| Child | 5 | 2018 | 25015 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 2316 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2015 | 8 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2015 | 55 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 125 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 118 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 1286 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 169 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2015 | 175 | 0.030 |
Why?
|
| Pyridines | 1 | 2015 | 242 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 415 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 822 | 0.030 |
Why?
|
| Side-Population Cells | 1 | 2013 | 12 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 649 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2013 | 92 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 285 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 559 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 358 | 0.020 |
Why?
|
| Luteinizing Hormone | 2 | 2002 | 133 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2013 | 560 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2002 | 185 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 907 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 215 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2002 | 417 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 98 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 75 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 229 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 328 | 0.020 |
Why?
|
| Adolescent | 4 | 2018 | 19904 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 585 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 991 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 649 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 1261 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 359 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6550 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2018 | 14316 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2009 | 1016 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 1235 | 0.020 |
Why?
|
| Testosterone | 2 | 2002 | 600 | 0.020 |
Why?
|
| Transcriptome | 1 | 2013 | 1063 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2005 | 8362 | 0.010 |
Why?
|
| Adult | 3 | 2018 | 30189 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2002 | 3295 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 9556 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1715 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 4295 | 0.010 |
Why?
|
| Quebec | 1 | 2002 | 5 | 0.010 |
Why?
|
| Growth Hormone | 1 | 2001 | 125 | 0.010 |
Why?
|
| Aged | 1 | 2018 | 19970 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 2001 | 166 | 0.010 |
Why?
|
| Testis | 1 | 2002 | 404 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2001 | 334 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2001 | 760 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 27263 | 0.010 |
Why?
|
| Infant | 1 | 2005 | 12758 | 0.000 |
Why?
|